These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17504107)

  • 1. Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission.
    Sur C; Kinney GG
    Curr Drug Targets; 2007 May; 8(5):643-9. PubMed ID: 17504107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM
    Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors.
    Wolkenberg SE; Sur C
    Curr Top Med Chem; 2010; 10(2):170-86. PubMed ID: 20166956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters.
    Harsing LG; Matyus P
    Brain Res Bull; 2013 Apr; 93():110-9. PubMed ID: 23266673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycine Transporters and Its Coupling with NMDA Receptors.
    Zafra F; Ibáñez I; Bartolomé-Martín D; Piniella D; Arribas-Blázquez M; Giménez C
    Adv Neurobiol; 2017; 16():55-83. PubMed ID: 28828606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycine transporter inhibitors as therapeutic agents for schizophrenia.
    Hashimoto K
    Recent Pat CNS Drug Discov; 2006 Jan; 1(1):43-53. PubMed ID: 18221190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine transporter type-1 and its inhibitors.
    Harsing LG; Juranyi Z; Gacsalyi I; Tapolcsanyi P; Czompa A; Matyus P
    Curr Med Chem; 2006; 13(9):1017-44. PubMed ID: 16611082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of glycine transporter-1 inhibitors.
    Sur C; Kinney GG
    Expert Opin Investig Drugs; 2004 May; 13(5):515-21. PubMed ID: 15155126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).
    Manahan-Vaughan D; Wildförster V; Thomsen C
    Eur J Neurosci; 2008 Oct; 28(7):1342-50. PubMed ID: 18973561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glutamate synapses in schizophrenia.
    Field JR; Walker AG; Conn PJ
    Trends Mol Med; 2011 Dec; 17(12):689-98. PubMed ID: 21955406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina.
    Reed BT; Sullivan SJ; Tsai G; Coyle JT; Esguerra M; Miller RF
    Eur J Neurosci; 2009 Dec; 30(12):2308-17. PubMed ID: 20092573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission.
    Leonetti M; Desvignes C; Bougault I; Souilhac J; Oury-Donat F; Steinberg R
    Neuroscience; 2006; 137(2):555-64. PubMed ID: 16289893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
    Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
    Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-synaptic glycine GlyT1 transporter--NMDA receptor interaction: relevance to NMDA autoreceptor activation in the presence of Mg2+ ions.
    Musante V; Summa M; Cunha RA; Raiteri M; Pittaluga A
    J Neurochem; 2011 May; 117(3):516-27. PubMed ID: 21348870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.
    Yee BK; Balic E; Singer P; Schwerdel C; Grampp T; Gabernet L; Knuesel I; Benke D; Feldon J; Mohler H; Boison D
    J Neurosci; 2006 Mar; 26(12):3169-81. PubMed ID: 16554468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
    Bridges TM; Williams R; Lindsley CW
    Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.